Parian Global Management’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
$1.11M Buy
240,724
+56,896
+31% +$335K 3.63% 9
2022
Q2
$930K Sell
183,828
-260,416
-59% -$1.9M 4.26% 11
2022
Q1
$3.17M Sell
444,244
-22,432
-5% -$151K 6.53% 6
2021
Q4
$4.55M Buy
+466,676
New +$4.15M 3.65% 9

Other funds holding STLN

Parian Global Management's STLN Position: Q3 2022 in Review

Parian Global Management increased its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 31% in Q3 2022, buying an estimated $335K and bringing the position to 240,724 shares worth $1.11M. The position accounts for 3.63% of the portfolio, ranked #9.

Parian Global Management first reported a position in STLN in Q4 2021 and has held it in 4 quarters since. The position peaked at $4.55M in Q4 2021. 39 funds tracked by Wall St. Rank hold STLN as of Q3 2022.

  • Parian Global Management held 240,724 shares of Starling Oncology Institute, Inc. Common Stock worth $1.11M as of Q3 2022.
  • Parian Global Management bought 56,896 Starling Oncology Institute, Inc. Common Stock shares in Q3 2022, an estimated $335K.
  • Starling Oncology Institute, Inc. Common Stock made up 3.63% of Parian Global Management's portfolio in Q3 2022, its #9 holding.
  • Parian Global Management first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2021 and has held it in 4 quarters since.
  • Parian Global Management's Starling Oncology Institute, Inc. Common Stock position peaked at $4.55M in Q4 2021.
  • 39 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q3 2022.

Based on Parian Global Management's 13F filing for Q3 2022, filed 14 Nov 2022.